Amova Asset Management Americas Inc. Trims Position in Twist Bioscience Corporation $TWST

Amova Asset Management Americas Inc. lessened its stake in Twist Bioscience Corporation (NASDAQ:TWST) by 10.3% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 1,902,829 shares of the company’s stock after selling 217,377 shares during the quarter. Amova Asset Management Americas Inc.’s holdings in Twist Bioscience were worth $60,263,000 at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of the stock. D.A. Davidson & CO. lifted its holdings in shares of Twist Bioscience by 1.2% in the fourth quarter. D.A. Davidson & CO. now owns 25,237 shares of the company’s stock worth $801,000 after buying an additional 305 shares in the last quarter. CWM LLC lifted its holdings in shares of Twist Bioscience by 9.4% in the fourth quarter. CWM LLC now owns 4,738 shares of the company’s stock worth $150,000 after buying an additional 407 shares in the last quarter. Smartleaf Asset Management LLC lifted its holdings in shares of Twist Bioscience by 70.6% in the third quarter. Smartleaf Asset Management LLC now owns 1,068 shares of the company’s stock worth $29,000 after buying an additional 442 shares in the last quarter. California State Teachers Retirement System lifted its holdings in shares of Twist Bioscience by 0.8% in the second quarter. California State Teachers Retirement System now owns 54,187 shares of the company’s stock worth $1,994,000 after buying an additional 442 shares in the last quarter. Finally, SBI Securities Co. Ltd. lifted its holdings in shares of Twist Bioscience by 68.9% in the fourth quarter. SBI Securities Co. Ltd. now owns 1,400 shares of the company’s stock worth $44,000 after buying an additional 571 shares in the last quarter.

Twist Bioscience Trading Up 0.0%

Shares of TWST opened at $70.06 on Wednesday. The company’s fifty day moving average is $58.12 and its 200 day moving average is $46.63. Twist Bioscience Corporation has a fifty-two week low of $23.30 and a fifty-two week high of $80.50. The stock has a market capitalization of $4.36 billion, a PE ratio of -52.68 and a beta of 2.23. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.42 and a current ratio of 2.70.

Twist Bioscience (NASDAQ:TWST) last announced its quarterly earnings results on Monday, May 4th. The company reported ($0.71) earnings per share for the quarter, missing the consensus estimate of ($0.49) by ($0.22). Twist Bioscience had a negative return on equity of 26.73% and a negative net margin of 19.85%.The business had revenue of $110.72 million during the quarter, compared to the consensus estimate of $107.64 million. During the same quarter in the prior year, the firm posted ($0.66) EPS. The company’s revenue for the quarter was up 19.3% on a year-over-year basis. Sell-side analysts expect that Twist Bioscience Corporation will post -1.99 earnings per share for the current fiscal year.

Insider Buying and Selling at Twist Bioscience

In other Twist Bioscience news, Director Robert Chess sold 10,000 shares of the business’s stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $47.00, for a total transaction of $470,000.00. Following the transaction, the director owned 21,084 shares in the company, valued at $990,948. The trade was a 32.17% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Jan Johannessen sold 12,000 shares of the business’s stock in a transaction on Tuesday, May 12th. The shares were sold at an average price of $56.12, for a total transaction of $673,440.00. Following the transaction, the director owned 17,754 shares in the company, valued at $996,354.48. This trade represents a 40.33% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 42,768 shares of company stock valued at $2,390,888. Insiders own 3.08% of the company’s stock.

Wall Street Analysts Forecast Growth

TWST has been the topic of several research analyst reports. Robert W. Baird boosted their target price on shares of Twist Bioscience from $50.00 to $65.00 and gave the stock an “outperform” rating in a report on Tuesday, May 5th. Barclays boosted their price target on shares of Twist Bioscience from $55.00 to $65.00 and gave the stock an “overweight” rating in a research report on Monday, May 4th. Guggenheim boosted their price target on shares of Twist Bioscience from $55.00 to $60.00 and gave the stock a “buy” rating in a research report on Tuesday, May 5th. Leerink Partners set a $80.00 price target on shares of Twist Bioscience in a research report on Friday, May 22nd. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Twist Bioscience in a research report on Friday, March 27th. Seven equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $58.00.

Twist Bioscience Profile

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.